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Essential thrombocytosis: Underemphasized 
cause of large-vessel thrombosis 
Marion Johnson, MD, Terry Gernsheimer, MD, and Kaj Johansen, MD, PhD, 
Seattle, Wash. 
Purpose: The purpose of this study was to describe the clinical course of patients een with 
large-vessel thrombosis in association with essential thrombocytosis (ET). 
Methods: This study was a retrospective r view of all patients treated for large-vessel 
thrombosis caused by ET during a 2-year period at University of Washington teaching 
hospitals. 
Results: Five patients presented with arterial (femoral-popliteal-tibial: aortic), portal (two 
cases), or systemic venous (inferior vena cava) thrombosis and required operation. Two 
were known to have ET; in three others ET was diagnosed after operation when platelet 
counts persistently in excess of 500,000/mm s were noted. The diagnosis of ET was 
established in each case by ruling out causes of reactive thrombocytosis and (in the three 
new cases) by evidence for megakaryocyte hyperplasia on bone marrow biopsy. Platelet 
counts in all five patients were reduced to normal levels by cytoreductive therapy, and no 
further thrombotic episodes have occurred uring 18 months (mean) of follow-up. During 
this 2-year period ET accounted for more large-vessel thrombotic omplications in our 
institutions than all other more frequently described hypercoagulable stat s combined. 
Conclusions: ET is an underemphasized cause of large-vessel thrombosis. (J VAsc SURG 
1995;22:443-9.) 
The hypercoagulable state is characterized by 
multiple or concurrent episodes of arterial or venous 
thrombosis, vascular occlusion at an early age or in 
unusual sites, or thrombosis in multiple family 
members. Much recent attention has been given to 
various thrombophilic states that may either be 
inherited (deficiencies of protein C, 1 protein S, 2 and 
antithrombin III, 3 or abnormal plasminogen 4) or 
acquired (heparin-associated hrombosis,  antiphos- 
pholipid antibodies, 6 or activated protein C resis- 
tance7). Although thrombosis in association with an 
abnormally elevated platelet count is well recognized 
by hematologists, 8-1° this phenomenon has rarely 
been mentioned in the vascular surgical literature. 
The myeloproliferative disorders (MPDs) are a 
heterogeneous array of conditions that include poly- 
cythemia vera, chronic myelogenous leukemia, my- 
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eloid metaplasia with myelofibrosis, and essential 
thrombocytosis. All may variably be associated with 
hemorrhagic or thrombotic omplications, the inci- 
dence of which may vary with the specific ondition. 
Essential thrombocytosis (ET) is defined by the 
absence of other MPDs or conditions that result in a 
reactive rise in platelet count and demonstration f
autonomous platelet production. Patients with ET 
have been reported to manifest symptoms and signs 
either of bleeding, usually as ecchymoses or mucosal 
hemorrhage, or of thrombosis, with the usual presen- 
tation being cutaneous or digital ischemia. Throm- 
bosis of large arteries or veins requiring operative 
intervention has only occasionally been reported in 
patients with ET. n,12 
Five patients treated with operation at University 
of Washington teaching hospitals for arterial or 
venous thrombosis were found to have ET. The 
clinical course of these patients illustrates the need for 
prompt recognition and appropriate reatment ofthis 
condition. 
CASE REPORTS 
In a 2-year period eight patients fulfilling diagnostic 
criteria for ET and manifesting symptoms and signs of 
major arterial or venous thrombosis were evaluated. Five 
underwent an operative intervention and are discussed in 
detail. 
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Fig. 1. Contrast aortogram in elderly woman with known 
ET and complaints of abdominal pain, intestinal angina, 
and kidney failure reveals large aortic mural thrombus 
occluding origins of celiac axis and superior mesenteric 
artery (case 2). At operation large platelet hrombus was 
found adhering to supraceliac aorta. 
Case 1. A 44-year-old white woman with a history of 
hypertension, obesity, and tobacco use presented with an 
ischemic right leg. She reported minor trauma to her right 
foot 13 days before admission with progressive symptoms 
of parasthesia, rest pain, and cutaneous infarction. The 
patient was admitted to an outside hospital, and when an 
arteriogram demonstrated diffuse femoral, popliteal, and 
tibial artery occlusion, thrombolytic therapy was at- 
tempted. This procedure was unsuccessful, and the patient 
was transferred. 
Hematologic workup demonstrated a platelet count of 
780,000/mm a. Further blood test results including pro- 
thrombin time, partial thromboplastin time, fibrinogen, 
antithrombin III, protein C, protein S, and white blood 
cells were within normal limits. Bone marrow biopsy 
demonstrated megakaryocyte hyperplasia. The patient 
underwent a right groin exploration with attempted 
thrombectomy; this procedure was unavailing, and a right 
through-knee amputation was ultimately required. Arte- 
riographic and histopathologic evaluation of her arteries 
demonstrated no evidence for atherosclerosis or other 
arterial wall disease. Treatment after surgery included 
aspirin and hydroxyurea. Three-year follow-up demon- 
strated no further episodes of thrombosis; her most recent 
platelet count was 277,000/mm 3. 
Case 2. A 68-year-old white woman with known ET 
presented with abdominal pain, intestinal angina, and mild 
kidney failure. She was found on aortography (Fig. 1) to 
have thrombus in the aorta with occlusion of the celiac and 
superior mesenteric arteries and splenic, renal, and hepatic 
infarcts consistent with embolic phenomena. Hematologic 
workup at the time of admission was significant for a 
platelet count of 1,000,000/mm 3. The patient underwent 
transaortic eliac and superior mesenteric artery explo- 
ration; large platelet thrombi were removed from the aorta 
itself and from the orifices of the visceral arteries. No 
evidence for aortic or mesenteric arteriosclerosis was noted 
at the time of operation. Postoperative treatment with 
hydroxyurea resulted in normalization of platelet count, her 
most recent value being 87,000/mm 3. She has manifested 
no further thrombotic events at 21/2 years of follow-up. 
Case 3. A 46-year-old male triathlete with known ET 
was admitted with upper gastrointestinal hemorrhage. Up- 
per endoscopy revealed grade 4 esophageal varices. Liver 
function studies were normal. Further imaging studies re- 
vealed thrombosis of the portal, superior mesenteric, and 
splenic veins and massive splenomegaly. Hematologic 
workup showed normal protein C and S and antithrombin 
II I  levels: the platelet count was 580,000/cu mm despite 
chronic treatment with hydroxyurea. Because of the neces- 
sity to control recurrent variceal hemorrhage, a modified 
Sugiura procedure was performed, including splenectomy, 
esophagogastric devascularization, and distal esophageal 
staple transection, la After operation the patient was main- 
tained on aspirin and an increased hydroxyurea dosage, 
with his most recent platelet count at 126,000/mm a. He 
was symptom free at 6-month follow-up. 
Case 4. A 33-year-old woman was admitted to another 
hospital with abdominal pain and jaundice. Liver functions 
were diffusely abnormal: iver biopsy showed centrilobnlar 
hepatocellular necrosis without cirrhosis. She was trans- 
ferred when she had massive upper gastrointestinal hem- 
orrhage seen on upper endoscopy to be arising from large 
esophageal and gastric varices. Splanchnic angiography 
revealed iffuse venous thrombosis with no "shuntable" 
vessel opacified. She had peritonitis and underwent emer- 
gency exploratory celiotomy, at which time extensive 
small-bowel infarction was discovered. Resection of all but 
120 cm of viable small bowel was undertaken: transection 
of mesentetic veins showed grey platelet-fibrin thrombi. 
Because of the presumption that the patient had had a 
venous intestinal infarction, operative steps were taken to 
reduce her portal hypertension by means of a modified 
Sugiura procedure (see Case 3). 
The patient had a complicated postoperative course 
because of "short-gut" syndrome, an anastomotic leak 
resulting in an enterocutaneous fistula, and thrombosis of 
both her right subclavian vein and her left iliofemoral 
venous system. Her platelet count was discovered to be 
JOURNAL OF VASCULAR SURGERY 
Volume 22, Number 4 Johnson, Gernsheimer, andJohansen 445 
780,000/mm a. Although this finding was thought initially 
to be a secondary postsplenectomy thrombocytosis, el-
evated preoperative platelet counts varying from 580,000 
to 840,000/cu mm were belatedly discovered; a platelet 
count drawn during an uncomplicated pregnancy 2 years 
previously had been 720,000/mm a. Bone marrow biopsy 
demonstrated megakaryocyte hyperplasia. ET was diag- 
nosed, and when postoperative platelet counts rose to 
1,200,000/mm 3, hydroxyurea w s started. Six months after 
operation she is maintaining her weight without parenteral 
nutrition and has a platelet count of 360,000/mm 3. 
Case 5. A 68-year-old woman with abdominal pain 
presented with what was diagnosed as a primary or 
secondary umor of the inferior vena cava and left renal vein 
ostium (Fig. 2). Operative xploration showed a caval mass 
that on histologic examination proved to be organized 
thrombus. It was then noted that her platelet count was 
734,000/mm a. All other studies upporting the diagnosis 
of a hypercoagulable state were negative, and bone marrow 
biopsy showed megakaryocyte hyperplasia. Aspirin and 
hydroxyurea reduced the platelet count to 220,000/mm a, 
and she has manifested no further thrombotic episodes at 
21/2-year follow-up. 
During the 2-year period under eview, three patients 
with other thrombophilic states (two with antithrombin 
III deficiency ~ and one with anticardiolipin antibody 6)had 
a large-vessel thrombosis and required operation in the 
University of Washington hospitals system. 
DISCUSSION 
A recent interest in various inherited and acquired 
hypercoagulable states has manifested itself in the 
vascular surgical literature 1417- appropriately so, be- 
cause patients afflicted with such disorders are 
increasingly likely to be seen by vascular surgeons, 
and reconstructive procedures undertaken in such 
patients are threatened by their underlying pro- 
thrombotic state. 16 Thrombophilias caused by defi- 
ciencies of various coagulation proteins >3 or the 
presence of abnormal antibodies or enzymes 4-7 has 
been emphasized. Accordingly, we were surprised to 
discover that, in our institution, the most common 
cause of  a hypercoagulable state resulting in symp- 
tomatic large-vessel occlusion during a recent 2-year 
period arose from essential or primary thrombocy- 
tosis. 
ET has been defined by the Polycythemia Vera 
Study Group 18 as a persistent thrombocytosis 
greater than 600,000 platelets/mm 3, confirmed by 
a bone marrow biopsy demonstrating megakaryo- 
cytic hyperplasia. However, hematologists do not 
strictly adhere to this platelet count requirement; a 
platelet count of 500,000/mm 3 or greater is con- 
sidered adequate for diagnosis. Furthermore the 
diagnosis of ET may be established simply by ruling 
Fig. 2. Inferior vena cavography in elderly woman with 
diffuse abdominal pain and intracaval mass onabdominal 
computed tomographic s anning shows bulky lesion con- 
sidered to be primary or secondary venous wall neoplasm 
before operation. At abdominal exploration lesion was 
found to be organized thrombus, and discovery of chroni- 
cally elevated platelet count led belatedly to diagnosis of 
ET. 
out lmown causes of reactive thrombocytosis. ET 
is a diagnosis of exclusion; more common secondary 
causes of an elevated platelet count (e.g., splenec- 
tomy, other myeloproliferative disorders, occult ma- 
lignancy) must be ruled out. Reactive thrombocy- 
tosis can also result from iron deficiency anemia, 
acute blood loss, inflammatory bowel disease, or 
various rheumatologic disorders. Although the 
terms "thrombocythemia" nd "thrombocytosis" 
have been used interchangeably for this condition, 
thrombocythemia is defined as an abnormal pro- 
liferation of  megakaryocytes on bone marrow 
biopsy; thrombocytosis is defined as an increase in 
the number of platelets in the blood and is ET only 
when this elevation in platelet count is a primary 
process. 
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ET was first described in 193419 and until recently 
was considered a relatively rare disorder. Presum- 
ably as a result of an increase in platelet counts 
obtained at the time of other blood tests, the 
condition is being detected more often in asymp- 
tomatic patients. By definition the platelet count is 
elevated; however, the risk of a bleeding or throm- 
botic complication does not necessarily correlate 
with the platelet count. 11 The discordance between 
platelet count and thrombotic risk has raised the 
question of platelet function in ET. Numerous 
studies addressing this issue have been performed; 
no consistent abnormalities have been found, and 
patients with ET generally exhibit normal bleeding 
times. Results of platelet aggregometry have been 
variable: Tobelem et al.20 report that platelet ag- 
gregation is elevated "in almost all cases," whereas 
Kaywin et al. 21 found diminished platelet aggre- 
gation in response to epinephrine and other con- 
ventional platelet aggregating agents. 
Complications of ET vary from small to large 
vessels, from arterial to venous ides of the circula- 
tion, and from hemorrhagic to thrombotic presen- 
tations. When hemorrhagic complications occur, they 
usually involve mucosal or gastrointestinal hemor- 
rhage, epistaxis, or postoperative bleeding. The most 
frequent hrombotic omplication is one of various 
disturbances of the microcirculation-livedo reticu- 
lar is,  22 erythromelalgia, 23 migraine, 24 or cerebrovas- 
cular ischemia. 2sIn a series reported by Hehlmann et 
al. ,26 thrombotic nvolvement ofthe microcirculation 
was the presenting factor in 67% of cases. Symptoms 
included digital cyanosis, pain, parasthesias, ulcer- 
ation, and frank gangrene. Thrombotic omplica- 
tions of large vessels have also been reported in from 
18% to 51% of patients in various series. 12,27,28 An 
obvious explanation for the differences among these 
studies is the rate of incidental discovery of asymp- 
tomatic patients with ET. 
Like platelet function studies, adjunctive risk 
factors for thrombotic and hemorrhagic complica- 
tions vary among reported series of patients with ET. 
Hehlmann et al. 26 correlated an increased risk for 
thrombotic events in patients with ET with concur- 
rent smoking, hypertension, or  d iabetes .  26 Mclntyre 
et al.24 studied complications a sociated with ET in a 
series of 56 patients younger than 40 years: "life- 
threatening" complications were observed in 5% of 
patients and "significant" complications in 33%.  24 
Nonetheless they concluded that because the risk of 
major complications in young patients is low, inter- 
vention should be reserved for those patients with 
significant hrombotic or hemorrhagic symptoms, 
because first-line medications carry their own set of 
risks. Patients with ET have 5- and 10-year survival 
rates only minimally less than age-matched patients 
in a cont ro l  groupl°'24'29: a small percentage of such 
patients undergo transformation to another MPD or 
to acute leukemia, °
Thrombotic events associated with ET suggest 
platelet hyperaggregation, although (as noted pre- 
viously) whether platelets in ET function abnor- 
mally remains in dispute. Thus the first line of 
therapy is the administration of platelet antiaggre- 
gating agents uch as aspirin; ticlopidine might be 
expected to be effective as well, although it has not 
been tested in this setting. Patients with microcir- 
culatory symptoms-migraine, erythromelalgia, li- 
vedo reticularis-tend to respond particularly well 
to this therapy. Anticoagulants have generally been 
ineffective in the management of the thrombotic 
complications of ET-perhaps not surprisingly in 
view of the apparently dominant role played by 
platelets in this condition. Anagrelide, an agent hat 
retards platelet aggregation by inhibiting cyclic 
nucleotide phosphodiesterase nd release of arachi- 
donic acid and also lowers platelet count by an 
unknown mechanism, is being evaluated for its 
safety and efficacy in patients with ET. al 
Acute reduction of platelet count is most readily 
effected by platelet pheresis a2 and is prudent when 
bleeding or thrombotic omplications occur in pa- 
tients with ET whose platelet count exceeds 1 
million. Prevention of recurrent thrombosis i best 
accomplished with aspirin or intravenous dextran. 
Prophylaxis i generally unwarranted in the authors' 
view, unless a markedly elevated platelet count occurs 
in a patient with other thrombotic risk factors, for 
example, symptomatic atherosclerosis. Long-term 
medical management, considered indicated once a 
major hemorrhagic or thrombotic omplication oc- 
curs, is based on the combination of antiaggregating 
agents, usually aspirin, and cytoreductive therapy 
such as radioactive phosphorus, alkylating agents, 
hydroxyurea, or interferon. Alkylating agents uch as 
busulfan and chlorambucil are effective in the control 
of ET; however, because of these agents' leuke- 
mogenic potential, they are not recommended in 
younger patients, aa whose condition at any rate 
generally pursues amore indolent course. 1°,24,29 Like 
other antimetabolites, hydroxyurea inhibits DNA 
synthesis and thereby sharply reduces megakaryocyte 
population and platelet count. This agent appears to 
be the treatment of choice in younger patients, 
because animal trials have demonstrated no associ- 
ated mutagenesis with hydroxyurea administration.a4 
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The constitutional effects associated with interferon 
treatment limit its efficacy. 
Mthough ET is a relatively benign condition, 
most of' whose complications can be managed 
medically by aspirin and cytoreductive therapy, 
occasionally patients with ET will present with major 
arterial or venous thromboses and require operative 
intervention. Alternatively, the surgeon may be 
confronted by a patient presenting de novo with 
large-vessel thrombosis in spite of the absence of 
obvious atherosclerotic or other thrombotic risk 
factors. In such a setting a thorough evaluation to 
characterize possible inherited or acquired hyperco- 
agulable states is prudent. Our experience suggests 
that assessing the platelet count is warranted: uring 
a 2-year period of time in our institution ET was the 
leading cause of a large-vessel thrombosis requiring 
operative intervention, accounting for more such 
cases than ~ other more commonly emphasized 
thrombophilic states combined. We consider ET an 
underemphasized cause of arterial and venous throm- 
bosis. 
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DISCUSSION 
Dr. Lloyd M. Taylor, Jr. (Portland, Ore.). Dr. 
Johnson and her colleagues have brought o our attention 
five cases in which major large-vessel thromboses requiring 
vascular surgical intervention occurred in patients with 
essential thrombocytosis. During the 2-year period these 
cases were accumulated, essential thrombocytosis was the 
most frequently recognized hypercoagulable state in their 
hospital. Based on this experience, the authors recommend 
that we screen patients with unexplained thromboses for 
essential thrombocytosis and that we treat it appropriately 
when discovered. 
Of course, unlike the situation with other so-called 
hypercoagulable states, screening for essential thrombocy- 
tosis is performed as a matter of routine on most 
hospitalized patients because of the inclusion of platelet 
counts in automated complete blood counts. This means 
that without doubt, this condition was in part the most 
frequently discovered hypercoagulable state in their pa- 
tients because it was the one most frequently looked for. 
Recognized hypercoagulable states include essential 
thrombocytosis, deficiencies of proteins C and S and 
antithrombin III, abnormalities of plasminogen and fi- 
brinogen, heparin-associated thrombosis, the presence of 
antiphospholipid antibodies, and hereditary resistance to 
activated protein C. Conventional practice recommends 
evaluation for these conditions when patients have multiple 
or concurrent episodes of arterial or venous thrombosis, 
vascular occlusion at an early age or in unusual sites, or 
familial thromboses. Others have recommended valuation 
in patients with arterial occlusions in the absence of 
atherosclerotic risk factors. Adherence to this practice 
means that these states will, of course, only be discovered 
in such patients. The danger of this approach to case finding 
is that an inappropriately morbid prognosis will be 
assigned to the conditions and that they will be inappro- 
priately considered to be rare. 
On our vascular surgery service, all patients undergoing 
operations have been screened for the presence of so-called 
hypercoagulable states ince 1990. The tests have included 
proteins C and S and antithrombin III, antiphospholipid 
antibodies, platelet count, and, since 1994, hereditary 
resistance to activated protein C. What we have discovered 
and reported is that while deficiencies of proteins C and S 
and antithrombin III are indeed rare, the presence of 
antiphospholipid antibodies occurs frequently in patients 
undergoing vascular surgical procedures, approximately 
one third being affected. The prevalence of hypercoagu- 
lable states appears just as high in older patients with 
atherosclerotic r sk factors as in those who are younger and 
lack atherosclerotic risk factors. What we have also 
discovered but not yet reported is that thrombotic om- 
plications including graft occlusion appear no more fre- 
quently in patients with so-called hypercoagulable states 
than in others with arterial disease requiring surgery. So by 
screening all patients and understanding the denominator, 
our understanding of these conditions is that they are not, 
as once believed, rare, and they may not, as once believed, 
be associated with a particularly poor prognosis. 
All of this brings me to my questions for the authors. 
Since presumably your hospital aboratory computer has 
recorded platelet counts on essentially all patients in your 
2-year study period, how many patients had platelet counts 
over i million but did not have thrombotic complications? 
Is essential thrombocytosis with thrombotic omplica- 
tions distinguishable from essential thrombocytosis a a 
laboratory curiosity? Are there circulating platelet aggre- 
gates in symptomatic patients, as some have suggested? 
Finally, what is your recommendation for treatment of 
patients discovered to have essential thrombocytosis in the 
absence of symptoms? Is this truly a hypercoagulable state, 
deserving of prophylactic treatment, or is essential throm- 
bocytosis a disorder that in an unknown number of those 
affected is associated with thrombosis? 
Dr. Marion Johnson. Dr. Taylor, your group has 
provided much about what we know about the denomi- 
nator of hypercoagulable states in the vascular patient 
population. 
Regarding the total number of high platelet counts 
seen in this period, we do not have that information from 
the University of Washington hospitals. However, Buss 
and colleagues recently reported their 5-year experience at 
Bowman Gray in the American Journal of Medicine. Among 
280 patients diagnosed with abnormally high platelet 
counts, 88% had reactive or secondary platelet elevations 
such as that which follows from splenectomy or malig- 
nancy; 12% had a primary myeloproliferative disorder. Sig- 
nificantly, the patients with a reactive or secondary throm- 
bocytosis had only a 4% risk of thrombotic omplications 
compared with the patients with a myeloproliferative dis- 
order who had a 54% risk of thrombotic omplications. 
Therefore, in answer to your other questions, essential 
thrombocytosis does indeed appear to confer a significant 
likelihood of thrombotic omplications, and at the least 
such patients' platelet counts should be followed serially. 
Once a complication has occurred, patients are at increased 
risk for repeat hrombotic complications, and their therapy 
should include aspirin or a cytoreductive agent. Surveil- 
lance for leukemogenic transformation should be under- 
taken. 
Dr. Wesley S. Moore (Los Angeles, Calif.). I wonder 
if you can help me in differentiating this condition from 
polycythemia rubra vera. It is well known that the risk of 
both thrombotic and hemorrhagic complication is fairly 
significant in polycythemia. My understanding is that one 
difference is that in the case of polycythemia we have both 
elevation of the red cell and white cell elements. But indeed 
in your patients if you had an increased megacaryocyte 
concentration i the bone marrow, might this not be 
considered a variant of polycythemia and, therefore, the 
thrombotic omplications be quite well explained? 
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Dr. Johnson. You are right. They are all myeloprolif- 
erative disorders, and as I pointed out, there is a 15% 
conversion to other myeloproliferative disorders. So essen- 
tial thrombocytosis exists on the continuum of myelopro- 
liferative disorders but is distinct from polycythemia rubra 
vera because it involves strictly the megakaryocytic com- 
ponent of the bone marrow and not the other blood cell 
precursors. I think thrombotic omplications arise both 
from the excessive platelet production and, perhaps, from 
abnormalities of the ET platelets themselves. 
Dr. Peter F. Lawrence (Salt Lake City, Utah). Dr. 
Johnson, in your series virtually all patients had an 
occlusion of either a large artery or large vein, and we have 
had a somewhat different experience at our institution. 
Most of our patients have presented with a lower extremity 
digital artery occlusion and ulceration of the lower extremi- 
ties or a toe ulcer that has been quite painful. I am 
wondering whether your series is typical of what is reported 
in the literature and whether large-vessel thromboses are 
more atypical than the more common digital artery 
occlusion. 
Second, when our patients have been treated with 
hydroxyurea, they have had remarkable improvement in
their symptoms and often have not required revasculariza- 
tion and have also not required amputation. I am curious 
as to whether the treatment with hydroxyurea orone of the 
more aggressive agents to deal with this problem results in 
recanalization of vessels or why patients have a complete 
resolution of their symptoms and healing of their ulcer 
without what would be any apparent improvement in 
blood flow. 
Dr. Johnson. Certainly microvascular thromboses 
associated with essential thrombocytosis are far more 
frequent, and perhaps the ulcers and digital ischemia 
involved more sludging in the microvasculamre than a 
large-vessel thrombosis, thereby accounting for that find- 
ing. Our study did not identify patients with microvascular 
thromboses, just strictly those with large-vessel thrombosis 
requiring operation. Recanalization could indeed account 
for improvement in symptoms of patients with such 
microvascular thrombosis. 
Dr. Wiley F. Barker (Los Angeles, Calif.). Dr. 
Lawrence's query stimulated me to offer the following 
instructive capsule history of a patient Dr. Quifiones and I 
shared. A woman in her seventies with a known history of 
thrombocytosis under treatment with hydroxyurea sud- 
denly had pain and discoloration of both feet. Distal pulses 
were present, although diminished. Careful study by 
arteriography and magnetic resonance imaging identified a
vague intraluminal filling defect in the infrarenal aorta. 
Operation disclosed amass composed ofplatelet thrombus. 
It was adherent at only one small point on the posterior wall 
and was easily lifted free. The point of attachment showed 
no lesion, and the remainder of the exposed aortic wall 
appeared entirely innocent. She recovered but died a few 
years later after a stroke. I suggest that peripheral lesions in 
the presence of thrombocytosis should be considered as 
possibly being thromboembolic from a major proximal 
vessel. 
Dr. Johnson. Certainly. That is a well-taken point, and 
reflects to a degree the scenario presented by our second 
patient. 
